| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2013.48.8585 |
| P698 | PubMed publication ID | 23918952 |
| P2093 | author name string | Min Tao | |
| Jin Li | |||
| Xiaodong Zhu | |||
| Ying Cheng | |||
| Xin Liu | |||
| Liwei Wang | |||
| Shukui Qin | |||
| Yan Yang | |||
| Guoping Sun | |||
| Jianming Xu | |||
| Hao Yu | |||
| Dongmei Ji | |||
| Yuxian Bai | |||
| Nong Xu | |||
| Zhehai Wang | |||
| Weijian Guo | |||
| Leizhen Zheng | |||
| Jianping Xiong | |||
| P433 | issue | 26 | |
| P921 | main subject | phase II clinical trial | Q42824440 |
| placebo | Q269829 | ||
| P304 | page(s) | 3219-3225 | |
| P577 | publication date | 2013-08-05 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial | |
| P478 | volume | 31 |
| Q36195933 | A Case Report of Gastrointestinal Hemorrhage and Perforation During Apatinib Treatment of Gastric Cancer |
| Q92402681 | A Single-Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer |
| Q33597266 | A case report of apatinib in treating osteosarcoma with pulmonary metastases |
| Q49724049 | A phase II study of apatinib in patients with recurrent epithelial ovarian cancer |
| Q91725994 | A retrospective study of low-dose apatinib combined with S-1 in patients with advanced non-small cell lung cancer |
| Q36215991 | A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate? |
| Q58547850 | A systematic review and meta-analysis on the effect of angiogenesis blockade for the treatment of gastric cancer |
| Q90697880 | An open label, multicenter, noninterventional study of apatinib in advanced gastric cancer patients (AHEAD-G202) |
| Q89538276 | Anorexia, Hypertension, Pneumothorax, and Hypothyroidism: Potential Signs of Improved Clinical Outcome Following Apatinib in Advanced Osteosarcoma |
| Q39067386 | Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review |
| Q37225659 | Antitumor activity and inhibitory effects on cancer stem cell-like properties of Adeno-associated virus (AAV) -mediated Bmi-1 interference driven by Bmi-1 promoter for gastric cancer |
| Q90699513 | Apatinib Inhibits Cell Proliferation and Induces Autophagy in Human Papillary Thyroid Carcinoma via the PI3K/Akt/mTOR Signaling Pathway |
| Q90390144 | Apatinib Mesylate in the treatment of advanced progressed lung adenocarcinoma patients with EGFR-TKI resistance -A Multicenter Randomized Trial |
| Q91739100 | Apatinib Monotherapy for Chemotherapy-Refractory Metastatic Colorectal Cancer: A Multi-centre, Single-Arm, Prospective Study |
| Q89180130 | Apatinib Plus Chemotherapy Shows Clinical Activity in Advanced NSCLC: A Retrospective Study |
| Q47728680 | Apatinib alone or combined with radiotherapy in metastatic prostate cancer: Results from a pilot, multicenter study. |
| Q57183556 | Apatinib as maintenance therapy in extensive-stage small-cell lung cancer: results from a single-center retrospective study |
| Q54977588 | Apatinib as targeted therapy for sarcoma. |
| Q90352665 | Apatinib combined with chemotherapy or concurrent chemo-brachytherapy in patients with recurrent or advanced cervical cancer: A phase 2, randomized controlled, prospective study |
| Q57111625 | Apatinib combined with docetaxel as a salvage treatment for metastatic esophageal squamous cancer: a case report |
| Q90783657 | Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study |
| Q47158606 | Apatinib concurrent gemcitabine for controlling malignant ascites in advanced pancreatic cancer patient: A case report |
| Q91079557 | Apatinib exerts anti-tumour effects on ovarian cancer cells |
| Q52681013 | Apatinib exhibits anti-leukemia activity in preclinical models of acute lymphoblastic leukemia. |
| Q90594483 | Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial |
| Q54117193 | Apatinib for advanced sarcoma: results from multiple institutions' off-label use in China. |
| Q57178943 | Apatinib for heavily treated patients with non-small cell lung cancer: Report of a case series and literature review |
| Q26775828 | Apatinib for molecular targeted therapy in tumor |
| Q58732685 | Apatinib for patients with advanced or recurrent cervical cancer: study protocol for an open-label randomized controlled trial |
| Q91676340 | Apatinib for treatment of a pseudomyxoma peritonei patient after surgical treatment and hyperthermic intraperitoneal chemotherapy: A case report |
| Q90114862 | Apatinib in patients with extensive-stage small-cell lung cancer after second-line or third-line chemotherapy: a phase II, single-arm, multicentre, prospective study |
| Q46156056 | Apatinib in the treatment of advanced lung adenocarcinoma with KRAS mutation |
| Q37086246 | Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma |
| Q41592916 | Apatinib inhibits VEGFR-2 and angiogenesis in an in vivo murine model of nasopharyngeal carcinoma |
| Q60950851 | Apatinib inhibits tumor growth and angiogenesis in PNET models |
| Q93143659 | Apatinib is effective as third-line and more treatment of advanced metastatic non-small-cell lung cancer: A retrospective analysis in a real-world setting |
| Q47146309 | Apatinib is effective for treatment of advanced hepatocellular carcinoma |
| Q58732707 | Apatinib monotherapy for advanced non-small cell lung cancer after the failure of chemotherapy or other targeted therapy |
| Q64070319 | Apatinib preferentially inhibits PC9 gefitinib-resistant cancer cells by inducing cell cycle arrest and inhibiting VEGFR signaling pathway |
| Q55383868 | Apatinib promotes apoptosis of the SMMC-7721 hepatocellular carcinoma cell line via the PI3K/Akt pathway. |
| Q41167283 | Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma |
| Q58779802 | Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma |
| Q42289797 | Apatinib to combat EGFR-TKI resistance in an advanced non-small cell lung cancer patient with unknown EGFR status: a case report |
| Q37712356 | Apatinib treatment combined with chemotherapy for advanced epithelial ovarian cancer: a case report |
| Q64112976 | Apatinib treatment of advanced hepatocellular carcinoma with portal vein and inferior vena cava tumor thrombus: A case report |
| Q99583852 | Apatinib versus sorafenib in patients with advanced hepatocellular carcinoma: a preliminary study |
| Q61806165 | Apatinib with EGFR-TKIs in advanced wild gene-type NSCLC: A case report |
| Q89435456 | Apatinib, a selective VEGFR2 inhibitor, improves the delivery of chemotherapeutic agents to tumors by normalizing tumor vessels in LoVo colon cancer xenograft mice |
| Q58739900 | Apatinib-based targeted therapy against pulmonary sarcomatoid carcinoma: a case report and literature review |
| Q57287885 | Apatinib-induced protective autophagy and apoptosis through the AKT-mTOR pathway in anaplastic thyroid cancer |
| Q58790284 | Apatinib-loaded lipid nanobubbles combined with ultrasound-targeted nanobubble destruction for synergistic treatment of HepG2 cells in vitro |
| Q49411843 | Apatinib-treated advanced medullary thyroid carcinoma: a case report |
| Q52583991 | Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers. |
| Q55279175 | Association between angiogenesis and cytotoxic signatures in the tumor microenvironment of gastric cancer. |
| Q52880999 | Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study. |
| Q33895597 | Biologic therapy in esophageal and gastric malignancies: current therapies and future directions |
| Q57456582 | Cardiovascular Toxicities with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Meta-Analysis of 77 Randomized Controlled Trials |
| Q91050877 | Changes in clinical trials of cancer drugs in mainland China over the decade 2009-18: a systematic review |
| Q26798288 | Chemotherapy beyond second-line in advanced gastric cancer |
| Q38604012 | Chemotherapy for advanced gastric cancer. |
| Q35288940 | Chemotherapy or targeted therapy as second-line treatment of advanced gastric cancer. A systematic review and meta-analysis of published studies |
| Q89493421 | Clinical Value Of Apatinib As A Salvage Treatment In Patients With Chemo-Refractory Advanced Cervical Cancer |
| Q34658366 | Clinical advances in the development of novel VEGFR2 inhibitors |
| Q60955467 | Clinical efficacy and safety of apatinib in patients with advanced colorectal cancer as the late-line treatment |
| Q64893996 | Clinical efficacy of apatinib in treating metastatic gastric cancer and its effect on IL-17. |
| Q42378476 | Clinical efficacy of endostar combined with chemotherapy in the treatment of peritoneal carcinomatosis in gastric cancer: results from a retrospective study |
| Q33922534 | Clinical impact of tumour biology in the management of gastroesophageal cancer |
| Q26765314 | Clinical modalities for management of gastric cancer hepatic metastasis |
| Q98386311 | Clinical observation of apatinib-related hypothyroidism in patients with advanced malignancies |
| Q41292062 | Clinical trials of tyrosine kinase inhibitors for lung cancer in China: a review |
| Q26785665 | Clinical utility of ramucirumab in advanced gastric cancer |
| Q97537942 | Combination of apatinib and docetaxel in treating advanced non-squamous non-small cell lung cancer patients with wild-type EGFR: a multi-center, phase II trial |
| Q64939558 | Combination of apatinib mesylate and second-line chemotherapy for treating gastroesophageal junction adenocarcinoma. |
| Q46832556 | Combined aspirin and apatinib treatment suppresses gastric cancer cell proliferation |
| Q89791281 | Combining transcatheter arterial embolization with iodized oil containing Apatinib inhibits HCC growth and metastasis |
| Q58759141 | Comparison of apatinib and capecitabine (Xeloda) with capecitabine (Xeloda) in advanced triple-negative breast cancer as third-line therapy: A retrospective study |
| Q58116134 | Comparison of efficacy and toxicity of bevacizumab, endostar and apatinib in transgenic and human lung cancer xenograftzebrafish model |
| Q37536970 | Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapy. |
| Q64091227 | Concurrent apatinib and docetaxel vs apatinib monotherapy as third- or subsequent-line therapy for advanced gastric adenocarcinoma: a retrospective study |
| Q47423570 | Cost-Effectiveness and Budget Impact Analysis of Apatinib for Advanced Metastatic Gastric Cancer from the Perspective of Health Insurance System. |
| Q26801289 | Critical evaluation of ramucirumab in the treatment of advanced gastric and gastroesophageal cancers |
| Q96132801 | Current Molecular Targeted Agents for Advanced Gastric Cancer |
| Q26765941 | Current Molecular Targeted Therapy in Advanced Gastric Cancer: A Comprehensive Review of Therapeutic Mechanism, Clinical Trials, and Practical Application |
| Q48117450 | Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial |
| Q40058691 | Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study |
| Q92329898 | Effect of Apatinib on Serum CD4+CD25+ T cells, NK Cells, and T Cells Subgroup in Malignant Tumor |
| Q90455818 | Efficacy and Safety of Apatinib Plus Vinorelbine in Patients With Wild-Type Advanced Non-Small Cell Lung Cancer After Second-Line Treatment Failure: A Nonrandomized Clinical Trial |
| Q90529033 | Efficacy and safety assessment of apatinib in patients with advanced gastric cancer: a meta-analysis |
| Q42378852 | Efficacy and safety for Apatinib treatment in advanced gastric cancer: a real world study |
| Q42362795 | Efficacy and safety of Apatinib in stage IV sarcomas: experience of a major sarcoma center in China |
| Q28079362 | Efficacy and safety of angiogenesis inhibitors in advanced gastric cancer: a systematic review and meta-analysis |
| Q90400076 | Efficacy and safety of apatinib combined with chemotherapy for the treatment of advanced gastric cancer in the Chinese population: a systematic review and meta-analysis |
| Q47174386 | Efficacy and safety of apatinib combined with transarterial chemoembolization for hepatocellular carcinoma with portal venous tumor thrombus: a retrospective study |
| Q104686280 | Efficacy and safety of apatinib for the treatment of AFP-producing gastric cancer |
| Q64963698 | Efficacy and safety of apatinib in treatment of osteosarcoma after failed standard multimodal therapy: An observational study. |
| Q48563213 | Efficacy and safety of apatinib monotherapy in advanced bone and soft tissue sarcoma: An observational study |
| Q41430542 | Efficacy and safety of apatinib treatment for advanced esophageal squamous cell carcinoma |
| Q57071382 | Efficacy and safety of apatinib treatment for gastric cancer, hepatocellular carcinoma and non-small cell lung cancer: a meta-analysis |
| Q55259389 | Efficacy and safety of sorafenib versus apatinib in the treatment of intermediate and advanced hepatocellular carcinoma: a comparative retrospective study. |
| Q52682256 | Efficacy and safety of targeting VEGFR drugs in treatment for advanced or metastatic gastric cancer: a systemic review and meta-analysis. |
| Q64256594 | Efficacy and toxicity of apatinib combined with or without chemotherapy for patients with advanced or metastatic chemotherapy-refractory gastric adenocarcinoma: A prospective clinical study |
| Q42371626 | Efficiency of low dosage apatinib in post-first-line treatment of advanced lung adenocarcinoma |
| Q35119526 | Establishment and characterization of patient-derived tumor xenograft using gastroscopic biopsies in gastric cancer |
| Q45771543 | Extraordinary response of metastatic pancreatic cancer to apatinib after failed chemotherapy: A case report and literature review |
| Q37204806 | Famitinib exerted powerful antitumor activity in human gastric cancer cells and xenografts |
| Q92551240 | First-line application of apatinib combined with S-1 based on peripheral circulating tumor cell screening to treat advanced gastric adenocarcinoma: a case report |
| Q27028079 | Gastric Cancer: New Drugs - New Strategies |
| Q39838743 | Gastric Carcinogenesis and Underlying Molecular Mechanisms: Helicobacter pylori and Novel Targeted Therapy. |
| Q26776195 | Gastric cancer: The times they are a-changin' |
| Q86003418 | Gastrointestinal cancer. Over the RAINBOW--renaissance in antiangiogenesis |
| Q89953612 | HER2/neu as target in gastric adenocarcinoma |
| Q41188373 | Hypoxia Promotes Gastric Cancer Malignancy Partly through the HIF-1α Dependent Transcriptional Activation of the Long Non-coding RNA GAPLINC. |
| Q91789276 | Immune-Mediated Antitumor Effect By VEGFR2 Selective Inhibitor For Gastric Cancer |
| Q92802225 | Incidence and Risk of Fatal Adverse Events in Cancer Patients Treated With Vascular Endothelial Growth Factor Receptor 2-Targeted Agents: A Meta-Analysis With Trial Sequential Analysis of Randomized Controlled Trials |
| Q90299813 | Influence and mechanism of lung cavitation development on antiangiogenic therapy: is cavitation the new caveat? |
| Q36065487 | Inhibition of β-catenin and STAT3 with a curcumin analog suppresses gastric carcinogenesis in vivo |
| Q98612912 | Large Scale, Multicenter, Prospective Study of Apatinib in Advanced Gastric Cancer: A Real-World Study from China |
| Q93135012 | Late-line treatment in metastatic gastric cancer: today and tomorrow |
| Q65000120 | Long-term progression-free survival of apatinib monotherapy for relapsed ovarian cancer: a case report and literature review. |
| Q90429351 | Long-term progression-free survival of third-line apatinib in lung squamous cell carcinoma |
| Q60912072 | Merkel cell carcinoma of the thigh: case report and review of the literature |
| Q42957434 | Metastatic gastric cancer treatment: Second line and beyond |
| Q26798420 | Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy |
| Q34544166 | Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer |
| Q47109075 | Multicenter phase II study of apatinib treatment for metastatic gastric cancer after failure of second-line chemotherapy |
| Q26799748 | Multimodal treatment of gastric cancer in the west: Where are we going? |
| Q26738548 | New advances in targeted gastric cancer treatment |
| Q92240594 | Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights |
| Q26786580 | Novel targeted agents for the treatment of lung cancer in China |
| Q26765208 | Novel targets in the treatment of advanced gastric cancer: a perspective review |
| Q54940671 | Overexpression of Kin of IRRE-Like Protein 1 (KIRREL) in Gastric Cancer and Its Clinical Prognostic Significance. |
| Q41091965 | Overwhelming rapid metabolic and structural response to apatinib in radioiodine refractory differentiated thyroid cancer |
| Q34326627 | Pathogenetic mechanisms in gastric cancer |
| Q64087290 | Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety |
| Q39630965 | Population Pharmacokinetic and Covariate Analysis of Apatinib, an Oral Tyrosine Kinase Inhibitor, in Healthy Volunteers and Patients with Solid Tumors |
| Q90529019 | Progress in the treatment of solid tumors with apatinib: a systematic review |
| Q35541950 | Progression-free survival as a surrogate endpoint for overall survival in patients with third-line or later-line chemotherapy for advanced gastric cancer |
| Q47115888 | Progression-free survival of up to 8 months of an advanced intrahepatic cholangiocarcinoma patient treated with apatinib: a case report. |
| Q55603677 | Proposed Molecular and miRNA Classification of Gastric Cancer. |
| Q37211153 | Ramucirumab for the treatment of gastroesophageal cancers |
| Q89445769 | Regorafenib: lights and shadows of antiangiogenic therapies in gastric cancer |
| Q33816865 | Reply to S. Zhang, L. Fornaro et al, and H.J. Lee et al |
| Q48145007 | Reporting of health-related quality of life in randomized controlled trials involving palliative systemic therapy for esophagogastric cancer: a systematic review. |
| Q42317538 | Response to apatinib in chemotherapy-failed advanced spindle cell breast carcinoma |
| Q89886969 | Retrospective review of the activity and safety of apatinib and anlotinib in patients with advanced osteosarcoma and soft tissue sarcoma |
| Q94546944 | Role of Systemic Treatment for Advanced/Metastatic Gastric Carcinoma in the Third-Line Setting: A Bayesian Network Analysis |
| Q64950564 | Safety and Efficacy of Apatinib Combined with Temozolomide in Advanced Melanoma Patients after Conventional Treatment Failure. |
| Q91713198 | Safety and effectiveness of apatinib in patients with previously treated metastatic gastric cancer: a sub-analysis from the real-world study of apatinib for gastric cancer treatment (AHEAD-G202) |
| Q37725637 | Salvage treatment with apatinib for advanced non-small-cell lung cancer |
| Q30249003 | Second- and third-line systemic therapy in patients with advanced esophagogastric cancer: a systematic review of the literature. |
| Q90705312 | Significant Efficacy of Apatinib in a Patient With Hepatocellular Carcinoma Lung Metastases After Liver Transplantation: A Case Report |
| Q41915464 | Significant efficacy and well safety of apatinib in an advanced liver cancer patient: a case report and literature review |
| Q37164989 | Significant partial response of metastatic intra-abdominal and pelvic round cell liposarcoma to a small-molecule VEGFR-2 tyrosine kinase inhibitor apatinib: A case report |
| Q61809370 | Significant response of low-dose apatinib monotherapy in brain metastases of triple-negative breast cancer: A case report |
| Q50350183 | Successful treatment of metastatic colorectal cancer with apatinib: report of two cases and literature review |
| Q48563226 | Successful treatment using apatinib with or without docetaxel in heavily pretreated advanced non-squamous non-small cell lung cancer: A case report and literature review |
| Q37653025 | Successful treatment with apatinib for refractory recurrent malignant gliomas: a case series |
| Q47149532 | Survival benefit of anti-angiogenic agents in patients with previously treated advanced gastric or gastroesophageal junction cancer: a meta-analysis |
| Q92432508 | Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study |
| Q52576043 | Synergistic antitumor effects of cMet inhibitor in combination with anti-VEGF in colorectal cancer patient-derived xenograft models. |
| Q41644087 | Systemic chemotherapy as a main strategy for liver metastases from gastric cancer |
| Q36471685 | Targeted therapies in gastric cancer and future perspectives. |
| Q38731943 | Targeted therapies in gastric cancer treatment: where we are and where we are going. |
| Q47623942 | Targeted therapies: Hope for antiangiogenic therapy in advanced gastric cancer. |
| Q26774138 | Targeted therapy for advanced gastric cancer: A review of current status and future prospects |
| Q36294579 | Targeted therapy in gastroesophageal cancers: past, present and future |
| Q89555538 | TfR1 binding with H-ferritin nanocarrier achieves prognostic diagnosis and enhances the therapeutic efficacy in clinical gastric cancer |
| Q64962531 | The Efficacy and Safety of Apatinib Treatment for Patients with Unresectable or Relapsed Liver Cancer: a retrospective study. |
| Q89538260 | The Impact of Ramucirumab Treatment on Survival and Quality of Life in Patients with Gastric Cancer |
| Q36993067 | The Use of Apatinib in Treating Nonsmall-Cell Lung Cancer: Case Report and Review of Literature |
| Q39134733 | The changing landscape of clinical trial and approval processes in China. |
| Q40539652 | The combinational therapy of trastuzumab and cetuximab inhibits tumor growth in a patient-derived tumor xenograft model of gastric cancer |
| Q55437410 | The coordinated effects of Apatinib and Tripterine on the proliferation, invasiveness and apoptosis of human hepatoma Hep3B cells. |
| Q36420167 | The distinct signatures of VEGF and soluble VEGFR2 increase prognostic implication in gastric cancer |
| Q36286390 | The effect of anti-angiogenic agents on overall survival in metastatic oesophago-gastric cancer: A systematic review and meta-analysis |
| Q93115476 | The effect of apatinib combined with chemotherapy or targeted therapy on non-small cell lung cancer in vitro and vivo |
| Q39455675 | The effect of apatinib in the treatment of metastatic renal cell carcinoma: a case report and review of the literature |
| Q49892901 | The efficacy and safety of targeted therapy with or without chemotherapy in advanced gastric cancer treatment: a network meta-analysis of well-designed randomized controlled trials |
| Q55410948 | The excellent antitumor effect of apatinib alone as second-line therapy in a patient with sorafenib-refractory hepatocellular carcinoma: A case report. |
| Q51738099 | The radiosensitive effect of apatinib for hepatocellular carcinoma patient with big paraspinal metastasis: A case report. |
| Q33415118 | The role of anti-VEGF agents in the treatment of advanced gastric cancer: a meta-analysis of randomized controlled trials |
| Q57452863 | The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study |
| Q92151408 | The use of apatinib in treating primary pleural synovial sarcoma: A case report |
| Q37082827 | Therapeutic effect of apatinib-loaded nanoparticles on diabetes-induced retinal vascular leakage |
| Q33818002 | Third-line chemotherapy in advanced gastric cancer: A systematic review and meta-analysis |
| Q50154574 | Traditional Chinese medicine integrated with chemotherapy for stage IV non-surgical gastric cancer: a retrospective clinical analysis. |
| Q98178300 | Transarterial Chemoembolization Combined With Apatinib for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis |
| Q47640556 | Treatment of medullary thyroid carcinoma with apatinib: A case report and literature review |
| Q34661367 | Treatment options in patients with metastatic gastric cancer: current status and future perspectives |
| Q49283018 | Treatment outcome of anti-angiogenesis through VEGF-pathway in the management of gastric cancer: a systematic review of phase II and III clinical trials |
| Q41769227 | Tumor microenvironment interruption: a novel anti-cancer mechanism of Proton-pump inhibitor in gastric cancer by suppressing the release of microRNA-carrying exosomes |
| Q64992191 | Use of apatinib combined with pemetrexed for advanced ovarian cancer: A case report. |
| Q33432199 | Vorinostat in combination with capecitabine plus cisplatin as a first-line chemotherapy for patients with metastatic or unresectable gastric cancer: phase II study and biomarker analysis |
| Q38247980 | What make differences in the outcome of adjuvant treatments for resected gastric cancer? |
| Q37412557 | miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer |
Search more.